Novartis AGNVSNYSE
Loading
Book Value/Share Growth Under PressureDecelerating
Percentile Rank67
5Y CAGR-0.3%
Year-over-Year Change
Year-over-year book value per share growth
5Y CAGR
-0.3%/yr
Long-term compound
Percentile
P67
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.72% |
| Q3 2025 | 7.63% |
| Q2 2025 | 10.49% |
| Q1 2025 | -12.02% |
| Q4 2024 | 2.85% |
| Q3 2024 | 4.75% |
| Q2 2024 | 5.97% |
| Q1 2024 | -14.71% |
| Q4 2023 | 22.95% |
| Q3 2023 | -25.60% |
| Q2 2023 | 0.89% |
| Q1 2023 | -11.21% |
| Q4 2022 | -0.96% |
| Q3 2022 | -1.96% |
| Q2 2022 | 3.36% |
| Q1 2022 | -8.53% |
| Q4 2021 | 19.12% |
| Q3 2021 | 5.47% |
| Q2 2021 | 7.42% |
| Q1 2021 | -10.21% |
| Q4 2020 | 4.79% |
| Q3 2020 | 1.42% |
| Q2 2020 | 5.06% |
| Q1 2020 | -8.64% |
| Q4 2019 | 5.94% |
| Q3 2019 | 3.83% |
| Q2 2019 | 9.25% |
| Q1 2019 | -40.09% |
| Q4 2018 | 1.08% |
| Q3 2018 | 1.98% |
| Q2 2018 | 7.94% |
| Q1 2018 | -4.23% |
| Q4 2017 | 3.14% |
| Q3 2017 | 4.26% |
| Q2 2017 | 4.24% |
| Q1 2017 | -9.56% |
| Q4 2016 | -0.07% |
| Q3 2016 | 3.58% |
| Q2 2016 | 0.81% |
| Q1 2016 | -6.55% |